NanoViricides, Inc. (NNVC)
USD 1.5
(0.67%)
USD 1.5
(0.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -8.29 Million USD | 3.43% |
| 2023 | -8.58 Million USD | -6.03% |
| 2022 | -8.1 Million USD | 9.06% |
| 2021 | -8.9 Million USD | 33.51% |
| 2020 | -13.39 Million USD | -62.5% |
| 2019 | -8.24 Million USD | 3.72% |
| 2018 | -8.56 Million USD | 16.9% |
| 2017 | -10.3 Million USD | 3.92% |
| 2016 | -10.72 Million USD | -387.89% |
| 2015 | -2.19 Million USD | 84.42% |
| 2014 | -14.1 Million USD | -58.93% |
| 2013 | -8.87 Million USD | -42.99% |
| 2012 | -6.2 Million USD | 4.17% |
| 2011 | -6.47 Million USD | -36.53% |
| 2010 | -4.74 Million USD | -70.18% |
| 2009 | -2.78 Million USD | -1.81% |
| 2008 | -2.73 Million USD | 12.2% |
| 2007 | -3.11 Million USD | 5.04% |
| 2006 | -3.28 Million USD | -4876.04% |
| 2005 | -66 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.96 Million USD | 44.85% |
| 2024 Q4 | -2.35 Million USD | -27.04% |
| 2024 Q3 | -1.85 Million USD | 12.32% |
| 2024 Q2 | -2.11 Million USD | -7.43% |
| 2023 Q3 | -1.59 Million USD | 3.71% |
| 2023 Q4 | -3.56 Million USD | -123.84% |
| 2023 Q2 | -1.65 Million USD | -9.04% |
| 2023 Q1 | -1.51 Million USD | 14.67% |
| 2023 FY | -8.58 Million USD | -6.03% |
| 2022 Q1 | -2.61 Million USD | -26.06% |
| 2022 FY | -8.1 Million USD | 9.06% |
| 2022 Q4 | -1.77 Million USD | 0.97% |
| 2022 Q2 | -1.92 Million USD | 26.48% |
| 2022 Q3 | -1.79 Million USD | 6.44% |
| 2021 Q2 | -2.33 Million USD | -0.81% |
| 2021 Q3 | -2.1 Million USD | 9.53% |
| 2021 Q1 | -2.31 Million USD | -23.29% |
| 2021 Q4 | -2.07 Million USD | 1.67% |
| 2021 FY | -8.9 Million USD | 33.51% |
| 2020 Q4 | -1.87 Million USD | 76.81% |
| 2020 FY | -13.39 Million USD | -62.5% |
| 2020 Q1 | -1.56 Million USD | 29.43% |
| 2020 Q2 | -1.92 Million USD | -23.47% |
| 2020 Q3 | -8.08 Million USD | -319.36% |
| 2019 Q2 | -2.23 Million USD | -21.15% |
| 2019 Q3 | -2.13 Million USD | 4.09% |
| 2019 FY | -8.24 Million USD | 3.72% |
| 2019 Q4 | -2.21 Million USD | -3.38% |
| 2019 Q1 | -1.84 Million USD | -11.53% |
| 2018 FY | -8.56 Million USD | 16.9% |
| 2018 Q4 | -1.65 Million USD | 21.75% |
| 2018 Q3 | -2.1 Million USD | 24.56% |
| 2018 Q2 | -2.79 Million USD | -39.46% |
| 2018 Q1 | -2 Million USD | 21.6% |
| 2017 Q4 | -2.55 Million USD | 18.5% |
| 2017 FY | -10.3 Million USD | 3.92% |
| 2017 Q1 | -3.06 Million USD | -85.46% |
| 2017 Q2 | -1.54 Million USD | 49.49% |
| 2017 Q3 | -3.13 Million USD | -102.97% |
| 2016 Q3 | -4.99 Million USD | -79.86% |
| 2016 Q2 | -2.77 Million USD | -112.35% |
| 2016 FY | -10.72 Million USD | -387.89% |
| 2016 Q4 | -1.65 Million USD | 66.93% |
| 2016 Q1 | -1.3 Million USD | -42.41% |
| 2015 Q4 | -917.71 Thousand USD | -265.6% |
| 2015 Q2 | -1.88 Million USD | -686.86% |
| 2015 FY | -2.19 Million USD | 84.42% |
| 2015 Q3 | -251.01 Thousand USD | 86.66% |
| 2015 Q1 | -239.07 Thousand USD | 95.91% |
| 2014 Q3 | -294.41 Thousand USD | 82.6% |
| 2014 FY | -14.1 Million USD | -58.93% |
| 2014 Q4 | -5.84 Million USD | -1885.97% |
| 2014 Q2 | -1.69 Million USD | 73.02% |
| 2014 Q1 | -6.27 Million USD | -187.64% |
| 2013 Q2 | -1.2 Million USD | 33.01% |
| 2013 Q4 | -2.18 Million USD | 40.78% |
| 2013 Q3 | -3.68 Million USD | -204.75% |
| 2013 FY | -8.87 Million USD | -42.99% |
| 2013 Q1 | -1.8 Million USD | -9.73% |
| 2012 Q1 | -1.13 Million USD | 9.35% |
| 2012 FY | -6.2 Million USD | 4.17% |
| 2012 Q4 | -1.64 Million USD | 19.09% |
| 2012 Q3 | -2.03 Million USD | -46.04% |
| 2012 Q2 | -1.39 Million USD | -22.05% |
| 2011 Q3 | -2.54 Million USD | -61.66% |
| 2011 Q1 | -1.09 Million USD | -65.53% |
| 2011 FY | -6.47 Million USD | -36.53% |
| 2011 Q2 | -1.57 Million USD | -43.54% |
| 2011 Q4 | -1.25 Million USD | 50.62% |
| 2010 Q1 | -731.18 Thousand USD | -17.02% |
| 2010 Q4 | -663.03 Thousand USD | 72.65% |
| 2010 Q3 | -2.42 Million USD | -161.99% |
| 2010 Q2 | -925.44 Thousand USD | -26.57% |
| 2010 FY | -4.74 Million USD | -70.18% |
| 2009 Q2 | -630.5 Thousand USD | 15.34% |
| 2009 Q4 | -624.82 Thousand USD | 20.68% |
| 2009 Q1 | -744.75 Thousand USD | 24.98% |
| 2009 FY | -2.78 Million USD | -1.81% |
| 2009 Q3 | -787.72 Thousand USD | -24.94% |
| 2008 Q3 | -790.88 Thousand USD | -108.15% |
| 2008 Q2 | -379.96 Thousand USD | 33.89% |
| 2008 FY | -2.73 Million USD | 12.2% |
| 2008 Q4 | -992.75 Thousand USD | -25.52% |
| 2008 Q1 | -574.73 Thousand USD | 25.49% |
| 2007 FY | -3.11 Million USD | 5.04% |
| 2007 Q2 | -689.13 Thousand USD | 6.92% |
| 2007 Q3 | -918.11 Thousand USD | -33.23% |
| 2007 Q4 | -771.33 Thousand USD | 15.99% |
| 2007 Q1 | -740.37 Thousand USD | 33.89% |
| 2006 Q4 | -1.11 Million USD | -42.05% |
| 2006 FY | -3.28 Million USD | -4876.04% |
| 2006 Q3 | -788.37 Thousand USD | 14.23% |
| 2006 Q2 | -919.12 Thousand USD | -101.11% |
| 2006 Q1 | -457.03 Thousand USD | 0.0% |
| 2005 FY | -66 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 71.362% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 3.914% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 87.987% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 83.01% |
| Azitra, Inc. | -11.28 Million USD | 26.495% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -8.647% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -12.375% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 71.611% |
| CEL-SCI Corporation | -32.36 Million USD | 74.374% |
| iBio, Inc. | -24.9 Million USD | 66.7% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 61.397% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 58.053% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 63.847% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 45.351% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | 13.961% |
| Oragenics, Inc. | -20.65 Million USD | 59.846% |
| BiomX Inc. | -26.16 Million USD | 68.305% |
| BiomX Inc. | -26.16 Million USD | 68.305% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 199.785% |
| Palatin Technologies, Inc. | -29.73 Million USD | 72.107% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 81.657% |